首页> 外文会议>IEEE Portuguese Meeting in Bioengineering >Protein and DNA nanoparticulate multiantigenic vaccines against H. pylori: In vivo evaluation
【24h】

Protein and DNA nanoparticulate multiantigenic vaccines against H. pylori: In vivo evaluation

机译:蛋白质和DNA纳米颗粒抗H.幽门螺杆菌的多抗疫苗:体内评价

获取原文

摘要

Immunisation against H. pylori is an attractive option for antibiotic resistance and reinfection situations. Strain genetic heterogeneity, and low immunogenicity of protein antigens and DNA alone are nonetheless obstacles to this approach. We developed multigenic H. pylori DNA-nanoparticle and protein-nanoparticle vaccines based on pathogenic relevance. Six antigens were chosen for the vaccine construction: CagA, VacA, HpaA, UreB, HomB and GroEL. Different combinations of CS/DS and CS/Alg /TPP nanoparticles with DNA and chimeric proteins were produced as vaccine systems. Immune responses were evaluated after i.m. and oral immunisation of BALB/c mice. Oral vaccination successfully stimulated mucosal immunity while i.m. immunisation efficiently elicited a more equilibrated cellular/humoral immune response.
机译:对H. Pylori的免疫是一种有吸引力的抗生素抗性和重新感染情况的选择。菌株遗传异质性,单独的蛋白质抗原和DNA的低免疫原性是这种方法的障碍。基于致病性相关性,我们开发了多键幽门螺杆菌DNA纳米粒子和蛋白质 - 纳米颗粒疫苗。选择六种抗原用于疫苗结构:Caga,Vaca,HPAA,UreB,HOMB和Groel。用DNA和嵌合蛋白的CS / DS和CS / ALG / TPP纳米粒子的不同组合作为疫苗系统制备。在此之后评估免疫应答。 BALB / C小鼠的口服免疫。在i.M的同时,口腔疫苗接种成功刺激粘膜免疫力。免疫有效引发更平衡的细胞/体液免疫应答。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号